FDA Approval Marks First CRISPR-Based Therapy for Sickle Cell Disease
The FDA approved Casgevy and Lyfgenia in December 2023, including the first FDA-approved CRISPR/Cas9 therapy for sickle cell disease in patients 12 and older.
Interactive visualizations, AI-powered research tools, and expert-led training for the next generation of biologists.
Start with core biology, move into advanced biotech topics, and learn through guided lessons designed for fast progress.
Applied biotechnology updates.
Open Coursearrow_forward schoolSkill-validation roadmap.
Open Coursearrow_forward schoolFoundational life-science concepts.
Open Coursearrow_forward schoolSelf-check practice blocks.
Open Coursearrow_forwardInstant explanations for complex biological pathways and concepts.
Summarize journals and find relevant papers in seconds.
Grammar checks and reference formatting for academic papers.
Automated sequence alignment and structure prediction.
AI Analysis Portal
Prompt
"Explain the mechanism of CRISPR-Cas9 in 3 bullet points."
Protein Folding Prediction
95% Accuracy
Published from the CMS workflow and editable by your admin account.
The FDA approved Casgevy and Lyfgenia in December 2023, including the first FDA-approved CRISPR/Cas9 therapy for sickle cell disease in patients 12 and older.
New findings suggest environmental toxic exposures can shift epigenetic aging markers.
Researchers report secondary social and health harms from drug deaths extending beyond mortality counts.
An antibody candidate was reported against two EBV entry antigens.
Antibody repertoires varied by age, sex, and genetics in a February 2026 release.
Neuroimaging data indicated additional structural adaptation in second pregnancy.
Go beyond the homepage feed and browse the full collection of news, discoveries, and analysis posts.
From thesis support to consulting, these service pages highlight the specialized help available through Biology Bytes.
Academic and industry profile optimization.
Open Servicearrow_forward constructionResearch process and methods consultancy.
Open Servicearrow_forward constructionScientific visuals and diagram support.
Open Servicearrow_forward constructionModeling and scenario workflows.
Open Servicearrow_forward